N
CTNM

Nuveen’s Contineum Therapeutics CTNM Stock Holding History

Nuveen’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13,307
Closed -$92.9K – 3441
2025
Q1 		$92.9K Hold
13,307
– – ﹤0.01% 3221
2024
Q4 		$195K Buy
+13,307
New +$211K ﹤0.01% 3210

Other funds holding CTNM

JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Nuveen's CTNM Position: Q2 2025 in Review

Nuveen sold out of Contineum Therapeutics (CTNM) in Q2 2025, closing a stake of 13,307 shares — an estimated $92.9K sold.

Nuveen first reported a position in CTNM in Q4 2024 and held it in 2 quarters. The position peaked at $195K in Q4 2024. 70 funds tracked by Wall St. Rank hold CTNM as of Q2 2025.

  • Nuveen reported no remaining Contineum Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Nuveen sold 13,307 Contineum Therapeutics shares in Q2 2025, an estimated $92.9K.
  • Nuveen first reported a position in Contineum Therapeutics in Q4 2024 and held it in 2 quarters.
  • Nuveen's Contineum Therapeutics position peaked at $195K in Q4 2024.
  • 70 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2025.

Based on Nuveen's 13F filing for Q2 2025, filed 12 Aug 2025.